The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
12 09 2023
Historique:
received: 29 06 2023
accepted: 29 08 2023
medline: 14 9 2023
pubmed: 13 9 2023
entrez: 12 9 2023
Statut: epublish

Résumé

Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few eCB compounds while largely ignoring the complexity of the eCB system. We examined the associations of multiple circulating eCBs and eCB-like molecules with early markers of neurodegeneration and neuro-injury and tested for effect modification by sex. This exploratory cross-sectional study included a random sample of 237 dementia-free older participants from the Framingham Heart Study Offspring cohort who attended examination cycle 9 (2011-2014), were 65 years or older, and cognitively healthy. Forty-four eCB compounds were quantified in serum, via liquid chromatography high-resolution mass spectrometry. Linear regression models were used to examine the associations of eCB levels with brain MRI measures (i.e., total cerebral brain volume, gray matter volume, hippocampal volume, and white matter hyperintensities volume) and blood biomarkers of Alzheimer's disease and neuro-injury (i.e., total tau, neurofilament light, glial fibrillary acidic protein and Ubiquitin C-terminal hydrolase L1). All models were adjusted for potential confounders and effect modification by sex was examined. Participants mean age was 73.3 ± 6.2 years, and 40% were men. After adjustment for potential confounders and correction for multiple comparisons, no statistically significant associations were observed between eCB levels and the study outcomes. However, we identified multiple sex-specific associations between eCB levels and the various study outcomes. For example, high linoleoyl ethanolamide (LEA) levels were related to decreased hippocampal volume among men and to increased hippocampal volume among women (β ± SE =  - 0.12 ± 0.06, p = 0.034 and β ± SE = 0.08 ± 0.04, p = 0.026, respectively). Circulating eCBs may play a role in neuro-injury and may explain sex differences in susceptibility to accelerated brain aging. Particularly, our results highlight the possible involvement of eCBs from the N-acyl amino acids and fatty acid ethanolamide classes and suggest specific novel fatty acid compounds that may be implicated in brain aging. Furthermore, investigation of the eCBs contribution to neurodegenerative disease such as Alzheimer's disease in humans is warranted, especially with prospective study designs and among diverse populations, including premenopausal women.

Sections du résumé

BACKGROUND
Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few eCB compounds while largely ignoring the complexity of the eCB system. We examined the associations of multiple circulating eCBs and eCB-like molecules with early markers of neurodegeneration and neuro-injury and tested for effect modification by sex.
METHODS
This exploratory cross-sectional study included a random sample of 237 dementia-free older participants from the Framingham Heart Study Offspring cohort who attended examination cycle 9 (2011-2014), were 65 years or older, and cognitively healthy. Forty-four eCB compounds were quantified in serum, via liquid chromatography high-resolution mass spectrometry. Linear regression models were used to examine the associations of eCB levels with brain MRI measures (i.e., total cerebral brain volume, gray matter volume, hippocampal volume, and white matter hyperintensities volume) and blood biomarkers of Alzheimer's disease and neuro-injury (i.e., total tau, neurofilament light, glial fibrillary acidic protein and Ubiquitin C-terminal hydrolase L1). All models were adjusted for potential confounders and effect modification by sex was examined.
RESULTS
Participants mean age was 73.3 ± 6.2 years, and 40% were men. After adjustment for potential confounders and correction for multiple comparisons, no statistically significant associations were observed between eCB levels and the study outcomes. However, we identified multiple sex-specific associations between eCB levels and the various study outcomes. For example, high linoleoyl ethanolamide (LEA) levels were related to decreased hippocampal volume among men and to increased hippocampal volume among women (β ± SE =  - 0.12 ± 0.06, p = 0.034 and β ± SE = 0.08 ± 0.04, p = 0.026, respectively).
CONCLUSIONS
Circulating eCBs may play a role in neuro-injury and may explain sex differences in susceptibility to accelerated brain aging. Particularly, our results highlight the possible involvement of eCBs from the N-acyl amino acids and fatty acid ethanolamide classes and suggest specific novel fatty acid compounds that may be implicated in brain aging. Furthermore, investigation of the eCBs contribution to neurodegenerative disease such as Alzheimer's disease in humans is warranted, especially with prospective study designs and among diverse populations, including premenopausal women.

Identifiants

pubmed: 37700370
doi: 10.1186/s13195-023-01301-x
pii: 10.1186/s13195-023-01301-x
pmc: PMC10496329
doi:

Substances chimiques

Endocannabinoids 0
Fatty Acids 0
Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

154

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS017950
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054076
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201500001C
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG049607
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG063507
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG058589
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201500001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00031
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG049505
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066546
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG033040
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG052409
Pays : United States
Organisme : NINDS NIH HHS
ID : UH2 NS100605
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG061872
Pays : United States

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Acta Pharmacol Sin. 2019 Mar;40(3):300-308
pubmed: 29941868
Neuropsychopharmacology. 2018 Sep;43(10):2017-2027
pubmed: 29977073
Curr Neuropharmacol. 2019;17(2):176-183
pubmed: 29962346
Mol Pharmacol. 2018 Mar;93(3):228-238
pubmed: 29138268
Prev Med. 1975 Dec;4(4):518-25
pubmed: 1208363
Metabolomics. 2015;11(6):1815-1833
pubmed: 26491425
Soc Work Health Care. 1992;17(3):81-96
pubmed: 1465717
Mol Metab. 2018 Aug;14:82-94
pubmed: 29935920
Brain Res Bull. 2021 Sep;174:305-322
pubmed: 34217798
Annu Rev Neurosci. 2012;35:529-58
pubmed: 22524785
Cell Biochem Funct. 2022 Mar;40(2):106-117
pubmed: 34931308
Bioorg Med Chem Lett. 2010 Oct 15;20(20):5959-68
pubmed: 20817522
Alzheimers Dement. 2020 Dec;16(12):1638-1649
pubmed: 32715635
Int J Mol Sci. 2021 Aug 31;22(17):
pubmed: 34502379
Nat Rev Neurol. 2018 Aug;14(8):457-469
pubmed: 29985474
Annu Rev Psychol. 2013;64:21-47
pubmed: 22804774
Alzheimers Dement. 2018 Sep;14(9):1193-1203
pubmed: 29803541
J Psychopharmacol. 2012 Jan;26(1):92-103
pubmed: 21447538
Lipids Health Dis. 2009 Jan 14;8:2
pubmed: 19144193
Nat Rev Drug Discov. 2004 Sep;3(9):771-84
pubmed: 15340387
Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:106-9
pubmed: 23365843
Int J Mol Sci. 2022 Feb 25;23(5):
pubmed: 35269720
Alzheimers Dement. 2019 Jun;15(6):817-827
pubmed: 31078433
Neuroimage. 2019 Jan 1;184:834-842
pubmed: 30296558
Neurobiol Aging. 2005 Apr;26(4):491-510
pubmed: 15653178
Biol Psychiatry. 2016 Apr 1;79(7):516-25
pubmed: 26698193
Acta Pharmacol Sin. 2020 Oct;41(10):1263-1271
pubmed: 32203086
Annu Rev Physiol. 2009;71:283-306
pubmed: 19575681
Dialogues Clin Neurosci. 2020 Sep;22(3):259-269
pubmed: 33162769
Science. 2009 Feb 13;323(5916):946-51
pubmed: 19213921
Semin Immunopathol. 2009 Jun;31(1):63-77
pubmed: 19357846
Nat Rev Neurosci. 2015 Jan;16(1):30-42
pubmed: 25524120
Mol Neurobiol. 2017 Dec;54(10):8332-8347
pubmed: 27924524
Neuropsychopharmacology. 2018 Jan;43(1):155-172
pubmed: 28653665
J Alzheimers Dis. 2015;43(4):1115-36
pubmed: 25147120
Alzheimers Dement. 2015 Mar;11(3):310-320
pubmed: 24418058
Ageing Res Rev. 2021 Aug;69:101346
pubmed: 33915266
Psychoneuroendocrinology. 2007 May;32(4):350-7
pubmed: 17391861
J Gerontol A Biol Sci Med Sci. 2022 Jun 1;77(6):1250-1253
pubmed: 35134198
Alzheimers Dement. 2018 Sep;14(9):1171-1183
pubmed: 29907423
Biomolecules. 2019 Dec 03;9(12):
pubmed: 31817019
Cells. 2022 Apr 06;11(7):
pubmed: 35406803
Life Sci. 1994;54(3):159-70
pubmed: 8289577
Am J Public Health Nations Health. 1951 Mar;41(3):279-81
pubmed: 14819398
Cell Metab. 2013 Apr 2;17(4):475-90
pubmed: 23562074
Exp Gerontol. 2014 Dec;60:92-9
pubmed: 25456842
Neurology. 2022 Oct 5;:
pubmed: 36198518
J Alzheimers Dis. 2017;56(3):947-957
pubmed: 28106548
Nat Commun. 2020 Mar 2;11(1):1148
pubmed: 32123170
Int J Mol Sci. 2021 Jan 19;22(2):
pubmed: 33478092
Talanta. 2020 Nov 1;219:121336
pubmed: 32887067
J Alzheimers Dis. 2015;46(2):497-506
pubmed: 25818503
Pharmacol Biochem Behav. 2021 Mar;202:173107
pubmed: 33444598

Auteurs

Shiraz Vered (S)

School of Public Health, University of Haifa, 199 Aba Khoushy Ave., Haifa, 3498838, Israel.

Alexa S Beiser (AS)

Department of Neurology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, 02118, USA.
Department of Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA.
The Framingham Study, Framingham, MA, 01702, USA.

Liron Sulimani (L)

The Kleifeld Laboratory, Department of Biology, Technion-Israel Institute of Technology, 3200003, Haifa, Israel.

Sharon Sznitman (S)

School of Public Health, University of Haifa, 199 Aba Khoushy Ave., Haifa, 3498838, Israel.

Mitzi M Gonzales (MM)

Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, 78229, USA.

Hugo J Aparicio (HJ)

Department of Neurology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, 02118, USA.
The Framingham Study, Framingham, MA, 01702, USA.

Charles DeCarli (C)

Department of Neurology, University of California at Davis, Sacramento, CA, 95816, USA.

Matthew R Scott (MR)

Department of Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA.

Saptaparni Ghosh (S)

Department of Neurology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, 02118, USA.
The Framingham Study, Framingham, MA, 01702, USA.

Gil M Lewitus (GM)

The Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, 3200003, Haifa, Israel.

David Meiri (D)

The Laboratory of Cancer Biology and Cannabinoid Research, Department of Biology, Technion-Israel Institute of Technology, 3200003, Haifa, Israel.

Sudha Seshadri (S)

Department of Neurology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, 02118, USA.
The Framingham Study, Framingham, MA, 01702, USA.
Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, 78229, USA.

Galit Weinstein (G)

School of Public Health, University of Haifa, 199 Aba Khoushy Ave., Haifa, 3498838, Israel. gweinstei@univ.haifa.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH